Loving the rise, and Paul Scott very positive10 Jan 2024 12:21
Great to see the continuing rise here, and on terrific volumes too.
FYI Paul Scott on Stock opedia summarised HVO positively ;ast week (I've had to leave out his charts):
"Paul’s Section hVIVO (LON:HVO)
£6.3m contract signed – Paul – GREEN
Checking our previous notes, we steadily became more enthusiastic about HVO as 2023 progressed, moving in stages from amber up to green by 13/12/2023 (ahead expectations update), and 12/9/2023 (good interims, and forecasts raised).
Well done to patient holders, as it’s had a smashing move up recently, in the almost everything rally we’ve seen in Nov-Dec 2023.
The positive newsflow continues today -
…signed a £6.3m contract with a biotechnology client to test its antiviral candidate using the hVIVO Human Rhinovirus (HRV – common cold virus) Human Challenge Study Model…
Revenue will be recognised in both FY 12/2024 and FY 12/2025.
HVO’s new state-of-the-art quarantine facilities in Canary Wharf will be used.
Broker update – Cavendish helps us with an update. It leaves forecasts unchanged, but they’re looking quite modest, given the strong newsflow. So I suspect beats against forecasts are likely for both 2023 and 2024.
As you can see below, there’s already been an impressive upward trend in forecasts, and I’m pretty sure this is all organic growth too.
Paul’s opinion – HVO really seems to be on a roll, and is producing very impressive newsflow. It’s increasingly looking like one of the UK market’s best growth companies.
Valuation doesn’t seem particularly stretched, once you factor in likely beats against forecast.
I also like that cash is received up-front from clients.
Despite a strong surge in share price, I remain positive on HVO shares, so it’s GREEN again.
Shares have been volatile in the past, but this current bull run looks much more firmly based on excellent company fundamentals"